Novonensis expects 2024 adjusted EBITDA margin of 35% (updated)

Novozymes A/S

21/03/2024 06:53

(Adds quote, further outlook details)
       COPENHAGEN, March 21 (Reuters) - Denmark's Novonensis
 NSISb.CO , created from the merger of food ingredients and
enzymes makers Novozymes and Chr. Hansen, on Thursday predicted
a 2024 adjusted margin on its earnings before interest, tax,
depreciation and amortization of around 35%.
    In 2023, the proforma EBITDA margin for the combined group
stood at 33.8%, the company said in a statement.    
    The company forecast organic sales growth of between 5% and
7% this year, after growing by 7% in 2023, it said in a
statement.
        "We expect a solid 2024 performance... and a strong
margin development," Novonensis said.
  

 (Reporting by Louise Breusch Rasmussen, editing by Terje
Solsvik)
 ((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))